Bintai Kinden, IJN to collaborate on Covid-19 vaccine development

Bintai Kinden executive director Azri Azerai presenting a mock cheque to IJN director of clinical research Datuk Dr Suhaini Kadiman as the initial grant under the Bintai Healthcare-IJN Covid 19 Research Grant to fund the necessary research programmes.

KUALA LUMPUR: Bintai Kinden Corp Bhd has entered into a collaboration with Institut Jantung Negara Sdn Bhd (IJN) to develop a Covid-19 vaccine in Malaysia.

In a statement, the group said it had entered into a collaborative agreement with the national heart institute to establish a partnership in the commercial development of the Ii-Key-SARS-CoV-2 coronavirus (Covid-19) vaccine.

It said the collaboration was based on an existing partnership between the company’s subsidiary Bintai Healthcare Sdn Bhd (“BHSB”), Generex Biotechnology Corp and NuGenerex Immuno-Oncology Inc.

Under the cooperative agreement, Bintai Kinden will be responsible for the introduction of the Covid-19 vaccine in Malaysia while IJN will perform and lead the clinical tests of the vaccine as required by the Health Ministry.

“After Generex has received the full Food and Drug Administration (FDA) approval on the vaccine and provides full documentation to BHSB, BHSB will commence the registration process to National Pharmaceutical Regulatory Agency (NPRA) of Malaysia for the vaccine,” said Bintai Kinden executive director Azri Azerai.